Investor’s Delight: Aquestive Therapeutics Inc (AQST) Closes Weak at 2.88, Down -1.03

Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The closing price of Aquestive Therapeutics Inc (NASDAQ: AQST) was $2.88 for the day, down -1.03% from the previous closing price of $2.91. In other words, the price has decreased by -$1.03 from its previous closing price. On the day, 2.84 million shares were traded. AQST stock price reached its highest trading level at $2.95 during the session, while it also had its lowest trading level at $2.73.

Ratios:

Our analysis of AQST’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.85 and its Current Ratio is at 6.28.

Upgrades & Downgrades

In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Leerink Partners on May 10, 2024, initiated with a Outperform rating and assigned the stock a target price of $8.

On April 11, 2024, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $10.

On March 28, 2024, Raymond James started tracking the stock assigning a Outperform rating and target price of $7.Raymond James initiated its Outperform rating on March 28, 2024, with a $7 target price.

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 15 ’24 when Schobel Alexander Mark sold 50,000 shares for $6.00 per share. The transaction valued at 300,000 led to the insider holds 984,476 shares of the business.

Schobel Alexander Mark sold 25,000 shares of AQST for $129,685 on Mar 08 ’24. The Chief Innovation/Tech Officer now owns 1,040,371 shares after completing the transaction at $5.19 per share.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AQST now has a Market Capitalization of 262190880 and an Enterprise Value of 201470976. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.09. Its current Enterprise Value per Revenue stands at 3.912 whereas that against EBITDA is -11.07.

Stock Price History:

Over the past 52 weeks, AQST has reached a high of $6.23, while it has fallen to a 52-week low of $1.25. The 50-Day Moving Average of the stock is -22.70%, while the 200-Day Moving Average is calculated to be 9.67%.

Shares Statistics:

AQST traded an average of 2.70M shares per day over the past three months and 1080790 shares per day over the past ten days. A total of 91.04M shares are outstanding, with a floating share count of 79.64M. Insiders hold about 12.52% of the company’s shares, while institutions hold 39.17% stake in the company. Shares short for AQST as of 1715731200 were 6183555 with a Short Ratio of 2.29, compared to 1713139200 on 4008551. Therefore, it implies a Short% of Shares Outstanding of 6183555 and a Short% of Float of 8.140001.

Most Popular